Literature DB >> 8613037

Survival and cause-specific mortality in inflammatory bowel disease: a population-based cohort study.

P G Persson1, O Bernell, C E Leijonmarck, B Y Farahmand, G Hellers, A Ahlbom.   

Abstract

BACKGROUND & AIMS: A population-based cohort study of 1251 subjects with Crohn's disease and 1547 subjects with ulcerative colitis, diagnosed in Stockholm between 1955 and 1984, was performed to examine the survival, changes in survival over time, and cause-specific mortality.
METHODS: The cohort of patients was followed up in the National Cause-of-Death register until 1990. National mortality rates were used for comparisons.
RESULTS: The observed vs. expected survival rate after 15 years was 93.7% (95% confidence interval [CI], 91.8%-95.7%) for Crohn's disease and 94.2% (95% CI, 92.4%-96.1%) for ulcerative colitis. Overall, 174 deaths occurred vs 115.42 expected (standardized mortality ratio, 1.51; 95% CI, 1.29-1.75) in Crohn's disease. In ulcerative colitis, 255 deaths occurred compared with 186.78 expected (standardized mortality ration, 1.37; 95% CI, 1.20-1.54). Inflammatory bowel disease was the major contributor to the elevated mortality rate, but mortality from colorectal cancer, asthma, and non-alcohol-related liver diseases was increased in ulcerative colitis; mortality from other gastrointestinal diseases was increased in ulcerative colitis as well as in Crohn's disease.
CONCLUSIONS: Data in the present study are compatible with the hypothesis that subjects with inflammatory bowel disease have an increased mortality compared with the general population.

Entities:  

Mesh:

Year:  1996        PMID: 8613037     DOI: 10.1053/gast.1996.v110.pm8613037

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  35 in total

1.  Protagonist: Early surgical intervention in ulcerative colitis.

Authors:  R R Cima; J H Pemberton
Journal:  Gut       Date:  2004-02       Impact factor: 23.059

2.  Balancing the risks and benefits of infliximab in the treatment of inflammatory bowel disease.

Authors:  W J Sandborn; E V Loftus
Journal:  Gut       Date:  2004-06       Impact factor: 23.059

3.  Current trends in inflammatory bowel disease: the natural history.

Authors:  Ebbe Langholz
Journal:  Therap Adv Gastroenterol       Date:  2010-03       Impact factor: 4.409

4.  Crohn's disease: increased mortality 10 years after diagnosis in a Europe-wide population based cohort.

Authors:  F L Wolters; M G Russel; J Sijbrandij; L J Schouten; S Odes; L Riis; P Munkholm; P Bodini; C O'Morain; I A Mouzas; E Tsianos; S Vermeire; E Monteiro; C Limonard; M Vatn; G Fornaciari; S Pereira; B Moum; R W Stockbrügger
Journal:  Gut       Date:  2005-09-08       Impact factor: 23.059

Review 5.  Crohn's disease: why the disparity in mortality?

Authors:  E V Loftus
Journal:  Gut       Date:  2006-04       Impact factor: 23.059

6.  Medical management of Crohn's disease.

Authors:  Paul A Feldman; Daniel Wolfson; Jamie S Barkin
Journal:  Clin Colon Rectal Surg       Date:  2007-11

Review 7.  Methodology for high-quality studies on course and prognosis of inflammatory bowel disease.

Authors:  Irene Modesto; Giovanni Perricone; Ambrogio Orlando; Mario Cottone
Journal:  World J Gastroenterol       Date:  2012-08-07       Impact factor: 5.742

8.  Mortality Risk of Inflammatory Bowel Disease: A Case-Control Study of New York State Death Records.

Authors:  Angelica Nocerino; Alexandra Feathers; Elena Ivanina; Laura Durbin; Arun Swaminath
Journal:  Dig Dis Sci       Date:  2019-01-02       Impact factor: 3.199

9.  Crohn's disease and ulcerative colitis are associated with elevated standardized mortality ratios: a meta-analysis.

Authors:  Meenakshi Bewtra; Lisa M Kaiser; Tom TenHave; James D Lewis
Journal:  Inflamm Bowel Dis       Date:  2013-03       Impact factor: 5.325

Review 10.  Hematopoietic cell transplantation for Crohn's disease; is it time?

Authors:  Y Leung; M Geddes; J Storek; R Panaccione; P L Beck
Journal:  World J Gastroenterol       Date:  2006-11-07       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.